Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Feb;22(1):14-20.

[Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy]

[Article in French]
Affiliations
  • PMID: 10221185
Clinical Trial

[Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy]

[Article in French]
M Montard et al. J Fr Ophtalmol. 1999 Feb.

Abstract

Purpose: To compare the efficacy and safety of topical diclofenac and tetracaine in reducing ocular pain after photorefractive keratectomy.

Setting: Ophthalmology Department, Minjoz Hospital, Besançon, France.

Methods: Seventy-four patients were randomized to receive either tetracaine 1% or diclofenac 0.1% after undergoing PRK. Tetracaine was instilled at 30 minute intervals for 24 hours. Diclofenac was instilled four times a day for 3 days. All patients were allowed to use oral Diantalvic (paracetamol-noramidopyrine) as a rescue analgesic if the study medications failed to control the ocular pain. Visual analog pain charts were used to record pain levels every hour for 30 hours after surgery. A subjective questionnaire was to be completed by the patient to evaluate discomfort every day for 3 days. Computer analysis of photography performed at D0, D1, D3, was used to evaluate the rate of epithelial closure.

Results: Women had significantly more pain. Patients in the diclofenac group had significantly less pain. No statistically significant difference was seen in the rate of epithelial closure.

Conclusion: Diclofenac is more effective than tetracaine to reduce ocular pain and functional symptoms.

PubMed Disclaimer

MeSH terms